Preface

For many years, leishmaniasis cases were basically restricted to developing countries. As a disease of extreme poverty, measures to control the insect vector, allocating resources for research, and protecting the environment were not adopted by government policies. The rise of unrestricted deforestation, globalization, and co-infections contributed to the spread of the disease to other countries in less than a century. Leishmaniasis is now a category Class I disease according to the World Health Organization (WHO) and is considered an uncontrolled emerging disease. These types of neglected diseases present many challenges, such as a lack of vector control strategies and vaccines for the most pathogenic *Leishmania* strains, parasite resistance, and ineffective treatment for canine leishmaniasis, which makes it increasingly difficult to control these diseases. This book discusses different aspects of *Leishmania* parasites. Chapters are organized into three sections: "Introduction", "Epidemiology and Immunopathology of Leishmaniases" and "New Insights on Leishmaniasis in Domestic Animals".

Section 1 contains the introductory chapter. The six chapters that follow in section 2 "Epidemiology and Immunopathology of Leishmaniases" focus on the epidemiology of leishmaniasis. Chapter 2 reviews the epidemiology of leishmaniasis, Chapter 3 discusses the epidemiology of visceral leishmaniasis in India, and Chapter 4 presents an interesting analysis of leishmaniasis epidemiology and psychosocial aspects of the disease. Chapter 5 is a review of cutaneous leishmaniasis, while Chapter 6 discusses visceral leishmaniasis, including its status, geographical distribution and transmission. Chapter 7 presents an in-depth review of the importance of species-specific leishmania antigens.

Section 3 includes two chapters that discuss leishmaniasis in domestic animals. Chapter 8 focuses on feline leishmaniasis, while Chapter 9 reviews the association between canine leishmaniasis and malignant disorders.

All chapters provide a unique perspective, resulting from the efforts of numerous leading researchers around the world. Overall, the book contributes to a better understanding of *Leishmania* parasites as well as aspects related to epidemiology, immunopathology, and challenges of the disease in humans and domestic animals.

> **Fernando Almeida-Souza and Ana Lucia Abreu-Silva** State University of Maranhão, São Luís, Brazil

**Flávia de Oliveira Cardoso and Kátia da Silva Calabrese** Oswaldo Cruz Institute, Rio de Janeiro, Brazil

**1**

Section 1

Introduction

Section 1 Introduction

#### **Chapter 1**

## Introductory Chapter: *Leishmania* Parasites – Epidemiology and Immunopathogenesis

*Fernando Almeida-Souza, Ana Lucia Abreu-Silva, Kátia da Silva Calabrese and Flávia de Oliveira Cardoso*

#### **1. Introduction**

Leishmaniases are a group of diseases caused by protozoan parasites from over 20 species belonging to subfamily Leishmaniinae [1, 2]. The parasites are transmitted by over 90 species phlebotomine sandflies from one host to the other by the bite of an infected female [3].

Clinical manifestations of leishmaniasis range from self-healing cutaneous lesions to potentially fatal visceral form. All clinical manifestations depend on the parasite species and the host's genetic and immunological response [4].

These pathologies affect predominantly the poorest people, mainly in tropical countries, exerting a high impact on mortality and morbidity rates. The risk factors for the development of the disease are associated with malnutrition, socioeconomic conditions, population mobility, environmental changes, and climate changes [3].

Due to the high global incidence and prevalence rates, mainly in developing countries, leishmaniases are among the 10 most neglected diseases (ND) in the world [5]. Worldwide, 99 countries are endemic to Leishmaniasis, where more than 12 million people are infected, and 20,000 to 30,000 deaths occur annually [3, 5]. Cutaneous leishmaniasis (CL) is endemic in 89 countries, visceral leishmaniasis (VL) in 80 countries, and both clinical forms are endemic in 71 countries. In the Americas, Brazil is the main country endemic for both CL and VL. Leishmania-HIV coinfection has intensified the burden of leishmaniasis, which have been reported by 42 countries around the world [3, 5].

These neglected diseases present many challenges, such as a lack of vector control strategies, different parasite strains, parasite resistance, and canine leishmaniasis treatment with low effectiveness, which makes it increasingly difficult to control these diseases.

#### **2. Experimental leishmaniasis**

Leishmaniasis affects a wide variety of hosts, whether they are natural reservoirs or "accidental" hosts in the *Leishmania* life cycle [3, 6].

Proposing an experimental model that can demonstrate what happens in both the wild host and the accidental host is a major challenge. The use of rodents as mice (*Mus* spp.) and hamster (*Cricetinae* spp.), as an experimental model, has been proposed as a good alternative to study the *Leishmania*-host relationship. Other models as dogs and primates are also used for leishmaniasis study, principally to test the efficacy of leishmanial vaccines [7–9]. In fact, there are a plethora of animal models for leishmaniasis study each of them with their peculiarities, advantages, and disadvantages. Mice with different genetic backgrounds are used for experimental studies involving parasites of the Leishmania genus, mainly susceptibility and resistance studies [4]. Different response profiles to the parasite infection are observed, and it is possible to classify these mice as sensitive, resistant, and intermediate. The hamster model is commonly used to study cutaneous leishmaniasis caused by *L. brasiliensis*, but it can also be used to isolate species that are difficult to cultivate [8]. The choice of model is related to which individual will provide the best answer to the question the researcher proposed. In leishmaniasis studies, mice and hamster are most commonly used [10]. There is, however, no consensus on the best animal model to be used, but regardless of the model chosen for the study, it is necessary to keep in mind animal welfare, the concept of the 3Rs, and approval of the experimental protocol by the Ethics Committee of Animal Use.

#### **3. Visceral leishmaniasis**

Visceral leishmaniasis (VL) is a life-threatening and tropical neglected disease, one of the world's six priority endemic diseases. In the New World, the protozoan Leishmania infantum infects several mammal species, including humans and dogs, which causes the visceral form. In urban areas, canines play a role in the transmission and maintenance of the parasite, which is evidence of a temporal correlation between the occurrence of human and canine visceral leishmaniasis [11]. In several countries, it is an uncontrolled disease and a severe public health issue. To establish public measures for the prophylaxis of this disease, screening the canine population and infected dogs is one of the primary forms of control of VL.

In human visceral leishmaniasis, the liver function and morphology are modified due to inflammatory reactions in the portal and intralobular region that may be locally concentrated or diffusely localized. Besides the involvement of this organ, the parasite could lead to augmenting the spleen; thus, hepatosplenomegaly is a frequent clinical sign. Other clinical signs described are irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anemia [3].

Unlike humans, which develop only visceral form, in canines, the first clinical signs observed are skin lesions such as periorbital alopecia, exudative dermatitis, hyperkeratosis of the footpad, and onychogryphosis. Other frequent signs are hepatosplenomegaly, enlargement of lymph nodes, weight loss, cachexia, epistaxis, pancytopenia, hypergammaglobulinemia, ocular lesions, and chronic renal failure [12–15].

#### **4. Treatment, an urgent need for new drugs**

Historically, several treatments against leishmaniasis have been used in the past, such as quinine, arsenicals, and turpentine injection. With variable results, none of them had proven effectiveness. In 1912, the doctor Gaspar Viana used the tartar

#### *Introductory Chapter:* Leishmania *Parasites – Epidemiology and Immunopathogenesis DOI: http://dx.doi.org/10.5772/intechopen.114096*

emetic, trivalent antimonial (SbIII), for the first time successfully in the therapy of ATL [16]. Between 1920 and 1930, pentavalent antimonials (SbV) were introduced in the treatment of visceral leishmaniasis, reducing treatment from 3 to 4 months to weeks. In the 1940s, new formulations of pentavalent antimonials appeared, which are less toxic and still used today: meglumine antimoniate, Glucantime®, and sodium stibogluconate, Pentostam® [17].

Despite the few advances in research on antimonials in recent decades, they are still the first-choice therapy against leishmaniasis. The treatment is long, with intramuscular administration, which sometimes requires hospitalization, causing discomfort to the patient, and high costs [18]. The other drugs available for leishmaniasis treatment are mainly amphotericin B and miltefosine.

Amphotericin B is an antifungal produced by culturing the actinomycetes *Streptomyces nodosus* used to combat systemic infections and is presented as amphotericin deoxycholate and in liposomal form. Liposomal amphotericin B was first used in the treatment of ATL by Sampaio & Mardsen [19]. It is the drug of choice in cases of parasite resistance to antimonials [20].

Miltefosine is an alkylphosphocholine originally developed as an antineoplastic chemotherapy drug. In the 1980s, during its evaluation for this therapeutic purpose, its potent action against leishmaniasis was discovered. In 2002, it was registered in India as the first oral treatment for visceral leishmaniasis [21]. Studies using miltefosine in the treatment of the cutaneous form of the disease resulted in good efficacy against *L. (V.) panamensis*, but for *L. (V.) braziliensis* there was no adequate efficacy [22].

Several active compounds have been tested against leishmaniasis, such as ketoconazole [23], itraconazole [24], fluconazole [25], terbinafine [26], and azithromycin [27], all with variable results. Thermal treatments, such as thermotherapy [28] and cryotherapy [29] have also been tested in the treatment of skin lesions; however, the lack of specificity and the need for professionals trained in the technique makes it difficult to advance the treatment. The search for new drugs should not be discontinued, as the disease progresses, and patients continue to wait for effective and low-toxicity medications.

#### **Acknowledgements**

This research was funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES (Finance Code 001), by Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (26/211.680/2021) and Fundação de Amparo à Pesquisa e Desenvolvimento Científico e Tecnológico do Maranhão (APP-12233/22). HSR (CNPq 150336/2023-3) and FA-S (FAPERJ E-26/203.513/2023) are postdoctoral research fellows. KC (315225/2021-1) and ALA-S (313348/2021-9) are research productivity fellows by Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq.

#### **Author details**

Fernando Almeida-Souza1,2\*, Ana Lucia Abreu-Silva1 , Kátia da Silva Calabrese2 and Flávia de Oliveira Cardoso2

1 Program of Animal Science, State University of Maranhão, São Luís, Brazil

2 Laboratory of Protozoology, IOC-Fiocruz, Rio de Janeiro, Brazil

\*Address all correspondence to: fernandoalsouza@gmail.com

© 2024 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Introductory Chapter:* Leishmania *Parasites – Epidemiology and Immunopathogenesis DOI: http://dx.doi.org/10.5772/intechopen.114096*

#### **References**

[1] Espinosa OA, Serrano MG, Camargo EP, Teixeira MMG, Shaw JJ. An appraisal of the taxonomy and nomenclature of trypanosomatids presently classified as Leishmania and Endotrypanum. Parasitology. 2018;**145**(4):430-442. DOI: 10.1017/ S0031182016002092

[2] Kostygov AY, Yurchenko V. Revised classification of the subfamily Leishmaniinae (Trypanosomatidae). Folia Parasitologica. 2017;**64**:020. DOI: 10.14411/fp.2017.020

[3] World Health Organization. Leishmaniasis. 2023 [Accessed: November 27, 2023]. Available from: https://www.who.int/news-room/ fact-sheets/detail/leishmaniasis

[4] Cardoso FO, Zaveruchado-Valle T, Almeida-Souza F, Abreu-Silva AL, Calabrese KDS. Modulation of cytokines and extracellular matrix proteins expression by Leishmania amazonensis in susceptible and resistant mice. Frontiers in Microbiology. 2020;**11**:1986. DOI: 10.3389/fmicb.2020.01986

[5] Pan American Health Organization. Leishmaniasis. 2023 [Accessed: November 27, 2023]. Available from: https://www.paho.org/en/topics/ leishmaniasis

[6] Labbé F, Abdeladhim M, Abrudan J, Araki AS, Araujo RN, Arensburger P, et al. Genomic analysis of two phlebotomine sand fly vectors of Leishmania from the New and Old World. PLOS Neglected Tropical Diseases. 2023;**17**(4):e0010862. DOI: 10.1371/journal.pntd.0010862

[7] Gupta S, Nishi. Visceral leishmaniasis: Experimental models for drug Discovery. Indian Journal of Medical Research. 2011;**133**:27-39

[8] Loría-Cervera EN, Andrade-Narváez FJ. Review animal models for the study of leishmaniasis immunology. Revista Instituto Medicina Tropical São Paulo. 2014;**56**(1):1-11. DOI: 10.1590/ s0036-46652014000100001

[9] van der Ende J, Schallig HDFH. Leishmania Animal Models Used in Drug Discovery: A Systematic Review. Animals 2023;**13**:1650. DOI: 10.3390/ ani13101650

[10] Nieto A, Domínguez-Bernal G, Orden JÁ, De La Fuente R, Madrid-Elena N, Carrión J. Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model. Veterinary Research. 2011;**42**(1):39. DOI: 10.1186/1297-9716-42-39

[11] Braz MS, Sáfadi T, Ferreira RA, Morais MHF, Silva Z, Rocha CMBMD. Temporal relationship between human and canine visceral leishmaniasis in an urban area in southeastern Brazil: An application of the ARIMAX model. Preventive Veterinary Medicine. 2023;**215**:105921. DOI: 10.1016/j. prevetmed.2023.105921. Epub 2023 Apr 12

[12] Ciaramella P, Oliva G, De Luna R, Ambrosio R, Cortese L, Persechino A, et al. A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum. Veterinary Record. 1997;**141**:539-543. DOI: 10.1136/vr.141.21.539

[13] Amusategui I, Sainz A, Rodríguez F, Tesouro MA. Distribution and relationships between clinical and

biopathological parameters in canine leishmaniasis. European Journal of Epidemiology. 2003;**18**(2):147-156. DOI: 10.1023/A:1023090929302

[14] Calabrese KS, Cortada VM, Dorval ME, Souza Lima MA, Oshiro ET, Souza CS, et al. Leishmania (Leishmania) infantum/chagasi: Histopathological aspects of the skin in naturally infected dogs in two endemic areas. Experimental Parasitology. 2010;**124**(3):253-257. DOI: 10.1016/j.exppara.2009.10.005. Epub 2009 Oct 23

[15] Diriba WW, Gebremedhin EZ. Assessment of knowledge, attitude, and practices towards canine visceral leishmaniasis based on the one health concept in Weliso and Ejaji towns, Oromia, Ethiopia. Scientific Reports. 2023;**13**(1):20765. DOI: 10.1038/ s41598-023-47340-0

[16] Vianna G. Tratamento da leishmaniose tegumentar por injeções intravenosas de tártaro emético. In: Anais do 7° Congresso Brasileiro de Medicina e Cirurgia. Vol. 4. 1912. pp. 426-428

[17] Murray HW. Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches. International Journal of Infectious Diseases. 2000;**4**:158-177

[18] Grimaldi G, Tesh RB. Leishmaniases of the New World: Current concepts and implications for future research. Clinical Microbiology Reviews. 1993;**6**:230-250

[19] Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Revista da Sociedade Brasileira de Medicina Tropical. 1997;**30**:125-128

[20] Torre-Cisneros J, Prada JL, Villanueva JL, Valverde F,

Sánchez-Guijó P. Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. Clinical Infectious Diseases. 1994;**18**:1024-1025

[21] Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bulletin of the World Health Organization. 2005;**83**:394-395

[22] Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases. 2004;**38**:1266-1272

[23] Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. The American Journal of Medicine. 1990;**89**:147-155

[24] Al-Fouzan AS, Al Saleh QA, Najem NM, Rostom AI. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. International Journal of Dermatology. 1991;**30**:519-521

[25] Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. The New England Journal of Medicine. 2002;**346**:891-895

[26] Bahamdan KA, Tallab TM, Johargi H, et al. Terbinafine in the treatment of cutaneous leishmaniasis: A pilot study. International Journal of Dermatology. 1997;**36**:59-60

[27] Sampaio RN, Lucas IC, Costa Filho AV. The use of azythromycin and N-methyl glucamine for the treatment of cutaneous Leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL6 mice. Anais Brasileiros de Dermatologia. 2009;**84**:125-128

*Introductory Chapter:* Leishmania *Parasites – Epidemiology and Immunopathogenesis DOI: http://dx.doi.org/10.5772/intechopen.114096*

[28] Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. The American Journal of Tropical Medicine and Hygiene. 1997;**57**:309-312

[29] Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. International Journal of Dermatology. 2004;**43**:281-283

Section 2
